Skip to main content

Table 1 Changes of mRNA expression in BJAB, OCI-LY3 and SU-DHL-6 cells after incubation with the c-MYC-inhibitor (5 µM), LY294002 (5 µM), Rapamycin (500 nM), PD98059 (10 µM) and SB203580 (10 µM) for 24 h

From: Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability

 

GLUT1

HK2

G6Ptase

LDHA

BJAB cells

c-MYC-inh.

ΔΔCT

1.71 ± 0.11 ↓

−0.45 ± 0.16 ↑

−1.69 ± 0.14 ↑

1.09 ± 0.14 ↓

Fold of untreated

0.31 (0.28–0.33)*

1.37 (1.22–1.53)*

3.23 (2.93–3.56)*

0.47 (0.43–0.52)*

LY294002

ΔΔCT

0.03 ± 0.10

0.08 ± 0.09

−0.41 ± 0.10 ↑

1.24 ± 0.17 ↓

Fold of untreated

0.98 (0.91–1.06)

0.95 (0.89–1.01)

1.33 (1.24–1.42)*

0.42 (0.38–0.48)*

Rapamycin

ΔΔCT

0.78 ± 0.09 ↓

0.84 ± 0.08 ↓

−0.72 ± 0.17 ↑

1.33 ± 0.14 ↓

Fold of untreated

0.58 (0.55–0.62)*

0.56 (0.53–0.59)*

1.65 (1.46–1.85)*

0.40 (0.36–0.44)*

PD98059

ΔΔCT

−0.02 ± 0.13

0.01 ± 0.10

−0.45 ± 0.09 ↑

0.04 ± 0.10

Fold of untreated

1.01 (0.93–1.11)

0.99 (0.93–1.06)

1.37 (1.28–1.45)*

0.97 (0.91–1.04)

SB203580

ΔΔCT

0.01 ± 0.08

−0.02 ± 0.07

0.05 ± 0.11

−0.09 ± 0.12

Fold of untreated

0.99 (0.94–1.05)

1.01 (0.97–1.06)

0.97 (0.90–1.04)

1.06 (0.98–1.16)

OCI-LY3 cells

c-MYC-inh.

ΔΔCT

1.12 ± 0.14 ↓

−0.43 ± 0.12 ↑

−1.23 ± 0.17 ↑

0.78 ± 0.12 ↓

Fold of untreated

0.46 (0.42–0.51)*

1.35 (1.24–1.46)*

2.35 (2.08–2.64)*

0.58 (0.54–0.63)*

LY294002

ΔΔCT

0.13 ± 0.15

−0.04 ± 0.10

−0.60 ± 0.10 ↑

1.03 ± 0.14 ↓

Fold of untreated

0.91 (0.82–1.01)

1.03 (0.96–1.10)

1.52 (1.41–1.62)*

0.49 (0.44–0.54)*

Rapamycin

ΔΔCT

0.49 ± 0.13 ↓

0.98 ± 0.15 ↓

−0.97 ± 0.10 ↑

1.56 ± 0.20 ↓

Fold of untreated

0.71 (0.65–0.78)*

0.51 (0.46–0.56)*

1.96 (1.83–2.10)*

0.34 (0.30–0.39)*

PD98059

ΔΔCT

−0.03 ± 0.18

0.01 ± 0.13

−0.03 ± 0.08

0.01 ± 0.16

Fold of untreated

1.02 (0.90–1.16)

0.99 (0.91–1.09)

1.02 (0.97–1.08)

0.99 (0.89–1.11)

SB203580

ΔΔCT

0.16 ± 0.14

0.44 ± 0.12 ↓

−0.08 ± 0.13

−0.03 ± 0.08

Fold of untreated

0.90 (0.81–0.99)

0.74 (0.68–0.80)*

1.06 (0.97–1.16)

1.02 (0.97–1.08)

SU-DHL-6 cells

c-MYC-inh.

ΔΔCT

1.23 ± 0.12 ↓

−0.36 ± 0.07 ↑

−0.93 ± 0.12 ↑

1.19 ± 0.08 ↓

Fold of untreated

0.43 (0.39–0.46)*

1.28 (1.22–1.35)*

1.91 (1.75–2.07)*

0.44 (0.41–0.46)*

LY294002

ΔΔCT

−0.11 ± 0.11

−0.05 ± 0.14

0.51 ± 0.08 ↑

0.98 ± 0.11 ↓

Fold of untreated

1.08 (1.00–1.16)

1.04 (0.94–1.14)

1.42 (1.35–1.51)*

0.51 (0.47–0.55)*

Rapamycin

ΔΔCT

0.66 ± 0.09 ↓

−0.83 ± 0.16 ↓

−0.82 ± 0.16 ↑

0.85 ± 0.09 ↓

Fold of untreated

0.63 (0.59–0.67)*

0.56 (0.50–0.63)*

1.77 (1.58–1.97)*

0.55 (0.52–0.59)*

PD98059

ΔΔCT

0.04 ± 0.16

0.09 ± 0.11

−0.05 ± 0.13

0.30 ± 0.10 ↓

Fold of untreated

0.97 (0.87–1.09)

0.94 (0.87–1.01)

1.04 (0.95–1.13)

0.81 (0.76–0.87)*

SB203580

ΔΔCT

−0.08 ± 0.15

0.05 ± 0.09

0.14 ± 0.14

0.17 ± 0.17

Fold of untreated

1.06 (0.95–1.17)

0.97 (0.91–1.03)

0.91 (0.82–1.00)

0.89 (0.79–1.00)

  1. ΔΔCT values referred to changes of mRNA levels corrected to expression of HPRT1 mRNA; changes of expression values represent percent of control, mean ± standard deviation from threefold determinations
  2. * and arrows indicate significant changes (p < 0.05, Mann–Whitney test)